Corium International (NASDAQ: CORI) is one of 105 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Corium International to similar businesses based on the strength of its profitability, risk, valuation, analyst recommendations, dividends, earnings and institutional ownership.
Volatility & Risk
Corium International has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Corium International’s rivals have a beta of 35.53, meaning that their average stock price is 3,453% more volatile than the S&P 500.
This table compares Corium International and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Corium International Competitors||-2,431.90%||-68.28%||-7.34%|
This is a breakdown of recent recommendations and price targets for Corium International and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Corium International Competitors||896||3887||6879||183||2.54|
Corium International presently has a consensus price target of $13.00, indicating a potential upside of 28.33%. As a group, “Pharmaceuticals” companies have a potential upside of 11.46%. Given Corium International’s stronger consensus rating and higher possible upside, research analysts clearly believe Corium International is more favorable than its rivals.
Earnings & Valuation
This table compares Corium International and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Corium International||$31.86 million||-$47.79 million||-6.07|
|Corium International Competitors||$8.31 billion||$1.11 billion||154.66|
Corium International’s rivals have higher revenue and earnings than Corium International. Corium International is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
89.4% of Corium International shares are owned by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 46.5% of Corium International shares are owned by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
About Corium International
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.
What are top analysts saying about Corium International? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corium International and related companies.